Full CoverageRoche's bispecific-ADC combo keeps cancer at bay in 2nd shot at 2nd-line large B-cell lymphoma
By Angus Liu
Top news
Roche’s Lunsumio and Polivy combination significantly prolongs remission for people with relapsed or refractory large B-cell lymphoma
Hematologists Highlight Notable Insights From the 2025 EHA Congress
By Ashling Wahner
Roche's Hemophilia Drug Shows Hemostatic Normalization Potential in Early-stage Study
All coverage
Phase III POLARGO Addition of Polatuzumab Vedotin Improves Overall Survival in Refractory DLBCL
By Caroline Helwick
“Remarkable” Survival Data for ADC Regimen in Relapsed/Refractory Diffuse Large B-Cell Lymphoma
By Leah Lawrence